In a retrospective analysis of several open-label, placebo controlled and compassionate-use trials of activated protein C (APC), intracranial hemorrhage was seen in 6% of patients treated with APC compared to 3% of patients receiving placebo or no APC. The gene discussed is PROC; the disease is intracranial hemorrhage.